A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess The Oral Corticosteroid-Sparing Effect Of Lebrikizumab In Patients With Severe Corticosteroid-Dependent Asthma
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Lebrikizumab (Primary) ; Corticosteroids
- Indications Asthma
- Focus Therapeutic Use
- Acronyms VOCALS
- Sponsors Roche
- 19 May 2017 Status changed from discontinued to completed.
- 11 May 2017 This trial has been completed in the Netherlands.
- 25 Apr 2017 This trial has been completed in Poland (End date:2016-12-21) as per European Clinical Trials Database record.